Federated Hermes Inc. Sells 834,724 Shares of Sanofi (NASDAQ:SNY)

Federated Hermes Inc. lessened its position in Sanofi (NASDAQ:SNY - Free Report) by 25.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,491,314 shares of the company's stock after selling 834,724 shares during the period. Federated Hermes Inc. owned about 0.10% of Sanofi worth $120,156,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Sanofi during the fourth quarter valued at $135,933,000. Boston Partners increased its position in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC lifted its stake in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after purchasing an additional 1,705,148 shares during the period. DAVENPORT & Co LLC boosted its holdings in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after buying an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Sanofi by 36.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock valued at $93,774,000 after buying an additional 514,542 shares during the period. Institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

Shares of NASDAQ SNY traded up $1.61 during mid-day trading on Friday, reaching $51.27. The company's stock had a trading volume of 1,358,412 shares, compared to its average volume of 2,312,977. The stock has a fifty day moving average of $55.01 and a two-hundred day moving average of $52.42. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm has a market capitalization of $129.53 billion, a PE ratio of 20.58, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SNY shares. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.